
Equillium Inc (EQ) Stock Forecast & Price Target
Equillium Inc (EQ) Analyst Ratings
Bulls say
Equillium is a promising biotechnology company with a strong focus on developing life-changing therapeutics for severe autoimmune and inflammatory disorders. Their drug candidate, EQ504, has shown promising results in pre-clinical studies and is targeting a high-demand market with few effective treatment options currently available. While the company may face funding challenges in the future, its potential for collaboration and expansion into other markets makes it a positive long-term investment opportunity.
Bears say
Equillium is a well-funded company with two promising drugs, obefazimod and EQ504, in its pipeline for treating severe autoimmune and inflammatory disorders. While concerns about potential side effects may have caused a drop in stock prices, the successful Phase 3 trial of obefazimod supports the potential efficacy of EQ504, leading to potential high peak sales. However, as a clinical-stage biotech company, there are inherent risks to investing in Equillium's stock.
This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.
Equillium Inc (EQ) Analyst Forecast & Price Prediction
Start investing in Equillium Inc (EQ)
Order type
Buy in
Order amount
Est. shares
0 shares